Avalo Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Garry A. Neil
- Full Time Employees
- 33
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1500 Liberty Ridge Drive Wayne PA United States of America 20850
- IPO Date
- Oct 14, 2015
- CIK
- 0001534120
- Website
- avalotx.com
- Similar Companies
- Business
- Avalo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering, developing, and commercializing targeted therapeutics for individuals experiencing significant unmet clinical needs in immune-mediated inflammatory diseases. The company strategically focuses on leveraging the Interleukin-1 beta (IL-1β) pathway, a key driver of inflammatory processes, to address chronic conditions. Avalo's primary clinical asset is AVTX-009, a high-affinity, potent humanized IgG monoclonal antibody engineered to specifically inhibit IL-1β. This investigational biologic is currently progressing through a global, randomized, double-blind Phase 2 clinical trial, known as the LOTUS trial, for the treatment of hidradenitis suppurativa (HS), a debilitating chronic inflammatory skin condition. Enrollment for the LOTUS trial concluded in October 2025, with topline data anticipated in mid-2026. Avalo is also actively exploring additional indications for AVTX-009 across other immune-mediated inflammatory diseases. The company’s strategic pipeline refinement in 2024 concentrated its resources on AVTX-009, following the divestiture or discontinuation of certain earlier-stage or legacy assets, including quisovalimab (formerly AVTX-002). Avalo Therapeutics, Inc. was initially incorporated in 2011 as Cerecor Inc. and officially adopted its current name in August 2021. The company maintains its headquarters in Wayne, Pennsylvania.
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
Avalo Therapeutics Appoints Ron Philip to Board of Directors
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
Avalo Therapeutics Purchases Optional Milestone Buyout
Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $42.25
Here Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More
Avalo Therapeutics (NASDAQ:AVTX) Insider Sells $10,864.00 in Stock
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
Ally Bridge Group NY LLC Purchases New Position in Avalo Therapeutics, Inc. $AVTX
Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at Conference
Silence Therapeutics (NASDAQ:SLN) versus Avalo Therapeutics (NASDAQ:AVTX) Head-To-Head Comparison